Moleculin Stock Market Sentiment

MBRX
 Stock
  

USD 1.55  0.02  1.31%   

Moleculin investor sentiment overview provides quick insight into current market opportunities from investing in Moleculin Biotech CS. The current market sentiment together Moleculin Biotech's historical and current headlines can help investors to time the market. Many technical investors use Moleculin Biotech stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Additionally, see Moleculin Biotech Hype Analysis, Moleculin Biotech Correlation and Moleculin Biotech Performance.
  
Refresh
Moleculin Biotech stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Moleculin daily returns and investor perception about the current pice of Moleculin Biotech CS as well as its diversification or hedging effects on your existing portfolios.

Moleculin Latest Sentiment Indicators

200 Day MA
1.88
Short Percent
0.0054
Short Ratio
3.06
Shares Short Prior Month
248.5 K
50 Day MA
1.46
52 Week Low
1.02
Shares Short
151.6 K
over a week ago at www.macroaxis.com         
Acquisition by Yan Joy of 15000 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Exercise or conversion by Foster Jonathan P of 12500 shares of Moleculin Biotech subject to Rule 16b...
Macroaxis News
over a month ago at www.cnbc.com         
Stock futures are slightly higher ahead of Mays jobs report - CNBC
cnbc News
over two months ago at www.defenseworld.net         
Moleculin Biotech Receives New Coverage from Analysts at StockNews.com - Defense World
news
over three months ago at www.nytimes.com         
Stocks Slide and Investors Seek Safety as Ukraine War Rages - The New York Times
nitimes news
over three months ago at www.macroaxis.com         
Acquisition by Yan Joy of 6667 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over six months ago at Macroaxis         
Will Moleculin Biotech (NASDAQ:MBRX) debt increase in January
Macroaxis News
over six months ago at www.macroaxis.com         
Exercise or conversion by Klemp Walter V of 13205 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Exercise or conversion by Klemp Walter V of 14718 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Acquisition by Foster Jonathan P of 50000 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over a year ago at www.macroaxis.com         
Acquisition by George Robert E of 10000 shares of Moleculin Biotech subject to Rule 16b-3
Macroaxis News
over a year ago at finance.yahoo.com         
Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Ma...
Yahoo News
There is far too much social signal, news, headlines, and media speculation about Moleculin Biotech that is available to investors today. That information is available publicly through Moleculin media outlets and privately through word of mouth or via Moleculin internal channels. However, regardless of the origin, that massive amount of Moleculin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Moleculin Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Moleculin Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Moleculin Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Moleculin Biotech alpha.

Moleculin Biotech Performance against DOW

 Price Growth (%)  
      Timeline 
1
Financial Statements04/08/2022
2
Financial Statements04/12/2022
3
Financial Statements04/21/2022
4
Financial Statements05/04/2022
5
Financial Statements05/05/2022
6
Financial Statements05/10/2022
7
EPS Reported05/11/2022
8
Financial Statements05/12/2022
9
Financial Statements05/20/2022
10
Financial Statements05/26/2022
11
Filing05/31/2022
12
Stock futures are slightly higher ahead of Mays jobs report ...06/02/2022
13
Financial Statements06/09/2022
14
Financial Statements06/16/2022
15
Exercise or conversion by Foster Jonathan P of 12500 shares ...06/21/2022
16
Acquisition by Yan Joy of 15000 shares of Moleculin Biotech ...06/22/2022
Additionally, see Moleculin Biotech Hype Analysis, Moleculin Biotech Correlation and Moleculin Biotech Performance. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.2 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.